Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lipid encapsulated cisplatin - Allarity Therapeutics /LiPlasome Pharma

Drug Profile

Lipid encapsulated cisplatin - Allarity Therapeutics /LiPlasome Pharma

Alternative Names: LiPlaCis

Latest Information Update: 05 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LiPlasome Pharma
  • Developer Allarity Therapeutics; Cadila Pharmaceuticals; LiPlasome Pharma
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Prostate cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 02 Jun 2023 Updated efficacy and adverse events data from the phase I/II LiPlaCis trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 25 May 2023 Updated efficacy data from a phase I/II trial in Solid tumours released by Allarity Therapeutics
  • 26 Oct 2020 Allarity Therapeutics receives patent allowance from the USPTO for Methods for predicting drug responsiveness in Cancer in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top